查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
抗体药物偶联物市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按技术、应用、配销通路和地理位置
市场调查报告书
商品编码
1372502

抗体药物偶联物市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按技术、应用、配销通路和地理位置

Antibody Drug Conjugates Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Technology, Application, Distribution Channel, and Geography
出版日期: | 出版商: The Insight Partners | 英文 178 Pages | 订单完成后即时交付

价格

全球抗体药物偶联物市场预计2022年将达到77.93亿美元，到2030年将达到296.00亿美元；预计2022年至2030年市场复合年增长率为18.2%。

抗体药物偶联物的市场成长归因于开发抗体药物偶联物的战略合作伙伴关係不断增强、癌症病例发病率上升以及 FDA 对 ADC 的批准增加。然而，ADC 开发和商业化的高成本阻碍了市场的成长。

加强策略伙伴关係开发抗体药物偶联物

抗体药物偶联物（ADC）在癌症治疗方面受到了全世界的广泛关注。自 2000 年美国食品药物管理局 (FDA) 批准 Mylotarg（辉瑞的第一个 ADC）以来，儘管发生了 COVID-19 大流行，製药业领导者的策略决策仍大幅增加。 2020年，多家製药公司建立了合作伙伴关係来开发ADC。例如，2020年7月，阿斯特捷利康和第一三共合作开发并商业化DS-1062。 DS-1602 是第一三共专有的滋养层细胞表面抗原 2 (TROP2) 导向的 ADC，用于治疗多种肿瘤类型。

同样，2022 年 12 月，默克 (MSD) 与四川科伦药业股份有限公司子公司科伦生物合作开发七种用于治疗癌症的研究性临床前 ADC。根据协议，默沙东获得科伦生物科技公司的全球独家许可，以研究、开发、製造和商业化多种临床前 ADC 疗法。此外，默沙东还拥有为 ADC 候选人获得额外许可的独家选项。而对于中国大陆、香港和澳门，科伦生物保留其研究、开发、製造和商业化某些许可和选择 ADC 的权利。

同样，2023年4月，BioNTech SE与Duuality Biologics（苏州）有限公司签署策略合作协议，开发下一代ADC来治疗癌症和自体免疫疾病。根据合作协议，BioNTech SE 将获得 DualityBio 的主要候选药物 DB-1303。 DB-1303 是一种基于拓朴异构酶 1 抑制剂的 ADC，针对人类表皮生长因子受体 2 (HER2)。 HER2 是大多数癌症类型中过度表达的共同标靶，有助于癌细胞的侵袭性生长和扩散。其次，BioNTech SE 将获得另一种基于拓朴异构酶 1 抑制剂的 ADC 候选药物 DB-1311。公司的目标是在全球范围内改造和商​​业化创新疗法。

抗体药物偶联物市场：细分概述

抗体药物偶联物市场根据技术、应用、配销通路和地理位置进行细分。根据技术，抗体药物偶联物市场分为可切割接头和不可切割接头。 2022年，可切割连接器细分市场占据了更大的市场份额，而不可切割连接器细分市场预计在2022-2030年期间复合年增长率更快。可切割接头利用化学触发或其结构的固有特性在肿瘤细胞中释放细胞毒性有效负载。该技术使用 pH 敏感性、谷胱甘肽敏感性和蛋白酶敏感性机製作为化学触发因素。可裂解接头技术广泛用于开发抗体药物偶联物（ADC）。根据 2021 年 3 月发表的文章《抗体-药物偶联物：连接基化学的最新进展》，超过 80% 的已批准 ADC 是使用可裂解连接基技术製成的。 Besponsa（inotuzumab ozogamicin）和 Adcetris（brentuximab vedotin）是使用此技术合成的 ADC 的两个着名范例。这些ADC在释放亲水性无痕有效负载后，在血液循环中长时间保持相对稳定。此外，可切割的接头可以在细胞内释放有效负载。

根据应用，抗体药物偶联物市场分为血癌、乳癌、卵巢癌、尿路上皮癌等。 2022年，乳癌细分市场占最大市场份额，预计2022-2030年复合年增长率最快，达18.6%。 ADC 的使用显着改变了乳癌治疗的计划方式。 ADC 的开发有望提高乳癌治疗的效力、精确度和安全性。目前，市面上治疗三阴性乳癌（TNBC）的商业化产品有Kadcyla/T-DM1（ado-trastuzumab emtansine）、Enhertu/T-DXd（trastuzumab deruxtecan）和Trodelvy/SG（sacituzumab govetican））和转移性乳癌病例。根据乳癌研究基金会 2023 年 1 月发布的资料，有 17 种 ADC 正在进行临床试验。其中 9 个是针对 HER2 的 ADC，正在以不同的有效负载组合进行研究。其余 8 种 ADC 则正在与新型抗体标靶结合进行研究。

抗体药物偶联物市场：地理概述

北美占据抗体药物偶联物市场的最大份额。该地区的抗体药物偶联物市场分为美国、加拿大和墨西哥。该地区的市场成长归因于 ADC 研发的增加、产品批准的增加、对 ADC 认识的提高以及营运商之间合併、合作和伙伴关係数量的增加。此外，癌症发生率的显着上升是导致 ADC 需求增加的其他主要因素之一。

美国是北美乃至全球抗体药物偶联物市场的最大贡献者。美国核准的 ADC 数量最多。到 2021 年 1 月，美国食品药物管理局 (FDA) 已批准 Mylotarg、Lumoxiti、Adcetris、Kadcyla、Enhertu、Trodelvy、Besponsa、Polivy、Padcev 和 Blenrep 用于多种癌症适应症。此外，美国还有多个 ADC 正在研发中。 ADC 的开发采用了先进的偶联技术、更有效的有效负载、针对新型抗原和新型接头等策略。根据 FDA 2021 年 5 月发布的资料，针对 77 种新型 ADC 正在进行 113 项临床试验，针对 40 多个不同标靶。预计，不断增加的 ADC 清单将在未来扩大该国抗体药物偶联物的市场规模。

此外，抗体药物偶联物市场领导者之间不断加强的合作关係将扩大他们在不同地区的技术，从而促进市场成长。 2023 年 8 月，ImmunoGen, Inc. 和武田製药有限公司在日本合作开发和商业化 Immunogen 的 ADC 疗法 ELAHERE。根据合作协议，ImmunoGen, Inc. 在获得 FDA 加速批准 ELAHERE 用于治疗铂类抗药性卵巢癌后将获得预付款和额外付款。如果武田透过ELAHERE 在日本的净销售额实现某些监管和商业里程碑以及两位数的特许权使用费，它将向ImmunoGen, Inc.支付额外款项。不过，Immunogen 保留其独家生产权，并将供应该产品进行开发和销售。在日本商业化。作为回报，武田将负责所有监管备案，并拥有在日本开发和商业化 ELAHERE 的独家许可。

在准备美国食品药物管理局 (FDA)、Cancer.Net、EMA（欧洲药品管理局）和疾病管制与预防中心 (CDC) 的 ADC 市场报告时提到的一些主要一手和二手来源。

目录

第 1 章：简介

  • Insight Partners 研究报告指南
  • 市场区隔

第 2 章：执行摘要

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：抗体药物偶联物市场格局

  • 概述
  • PEST分析
    • 全球PEST分析
  • 供应商名单
    • 价值链供应商名单

第 5 章：抗体药物偶联物市场 - 主要产业动态

  • 主要市场驱动因素：
    • 加强策略伙伴关係开发抗体药物偶联物
    • 癌症发生率上升
    • FDA 增加对 ADC 的核准
  • 市场限制
    • ADC 开发和商业化成本高昂
  • 市场机会
    • 增加开发 ADC 的投资
  • 市场走向
    • 不断升级的 ADC 产品线
  • 影响分析：

第 6 章：抗体药物偶联物市场 - 全球市场分析

  • 抗体药物偶联物市场收入，2017 - 2030

第 7 章：抗体药物偶联物市场 - 收入和 2030 年预测 - 按技术

  • 概述
  • 2022 年和 2030 年按技术分類的抗体药物偶联物市场收入份额 (%)
  • 可切割接头
  • 不可切割的接头

第 8 章：抗体药物偶联物市场 - 收入和 2030 年预测 -按应用

  • 概述
  • 2022 年及 2030 年抗体药物偶联物市场收入份额（按应用划分）
  • 血癌
  • 乳癌
  • 卵巢癌
  • 尿路上皮癌
  • 其他的

第 9 章：抗体药物偶联物市场 - 收入和 2030 年预测 - 按配销通路

  • 概述
  • 2022 年及 2030 年抗体药物偶联物市场收入份额，依配销通路(%)
  • 医院药房
  • 零售药局
  • 网路药局

第 10 章：抗体药物偶联物市场 - 区域分析

    • 概述
    • 北美：抗体药物偶联物市场（按技术）
    • 北美：抗体药物偶联物市场（按应用）
    • 北美：抗体药物偶联物市场（按配销通路）
    • 北美：抗体药物偶联物市场（按国家）
      • 我们
      • 加拿大
      • 墨西哥
    • 概述
    • 欧洲：抗体药物偶联物市场（按技术）
    • 欧洲：抗体药物偶联物市场（依应用）
    • 欧洲：抗体药物偶联物市场（按配销通路）
    • 欧洲：抗体药物偶联物市场（依国家）
      • 英国
      • 德国
      • 法国
      • 义大利
      • 西班牙
      • 欧洲其他地区
    • 概述
    • 亚太地区：抗体药物偶联物市场（依技术）
    • 亚太地区：抗体药物偶联物市场（依应用）
    • 亚太地区：抗体药物偶联物市场（按配销通路）
    • 亚太地区：抗体药物偶联物市场（依国家）
      • 中国
      • 日本
      • 印度
      • 韩国
      • 澳洲
      • 亚太地区其他地区
    • 概述
    • 中东和非洲：抗体药物偶联物市场（按技术）
    • 中东和非洲：抗体药物偶联物市场（按应用）
    • 中东和非洲：抗体药物偶联物市场（按配销通路）
    • 中东和非洲：抗体药物偶联物市场（按国家）
      • 沙乌地阿拉伯
      • 阿联酋
      • 南非
      • 中东和非洲其他地区
    • 概述
    • 南美洲和中美洲：抗体药物偶联物市场（按技术）
    • 南美洲和中美洲：抗体药物偶联物市场（按应用）
    • 南美洲和中美洲：抗体药物偶联物市场（按配销通路）
    • 南美洲和中美洲：抗体药物偶联物市场（按国家）
      • 巴西
      • 阿根廷
      • 南美洲和中美洲其他地区

第 11 章：抗体药物偶联物市场-产业格局

  • 概述
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述
  • 公司製造能力及能力

第 12 章：公司简介

  • ADC Therapeutics SA
  • Pfizer Inc
  • Hoffmann-La Roche Ltd
  • ImmunoGen, Inc.
  • GSK Plc
  • Gilead Sciences Inc
  • AstraZeneca Plc
  • Astellas Pharma Inc
  • RemeGen Co Ltd
  • Takeda Pharmaceutical Co Ltd

第 13 章：附录

  • 关于我们
  • 专业术语
Product Code: TIPRE00003494

The global antibody drug conjugates market is expected to reach US$ 7.793 billion in 2022 to US$ 29.600 billion by 2030; the market is estimated to record a CAGR of 18.2% from 2022 to 2030.

The market growth of antibody drug conjugates is attributed to growing strategic partnerships to develop antibody drug conjugates, rising incidences of cancer cases, and increasing FDA approvals for ADCs. However, high cost of ADCs development and commercialization is hindering the market growth.

Growing Strategic Partnerships to Develop Antibody Drug Conjugates

Antibody-drug conjugates (ADCs) have received significant attention worldwide for cancer therapy. Since the approval of Mylotarg (Pfizer, Inc.'s first ADC) by the US Food and Drug Administration (FDA) in 2000, there has been substantial growth in strategic decisions by pharmaceutical leaders despite the COVID-19 pandemic. In 2020, various pharmaceutical companies entered into partnerships to develop ADCs. For intance, in July 2020, AstraZeneca and Daiichi Sankyo collaborated to develop and commercialize DS-1062. DS-1602 is Daiichi Sankyo's proprietary trophoblast cell-surface antigen 2 (TROP2)-directed ADC to treat multiple tumor types.

Likewise, in December 2022, Merck & Co., Inc. (MSD) and Kelun-Biotech, a Sichuan Kelun Pharmaceutical Co., Ltd. subsidiary, partnered to develop seven investigational preclinical ADCs to treat cancer. Under the agreement, MSD received a grant for exclusive global licenses from Kelun Biotech to research, develop, manufacture, and commercialize multiple investigational preclinical ADC therapies. In addition, MSD has exclusive options to obtain additional licenses for ADC candidates. Whereas for Mainland China, Hing Kong, and Macau, Kelun-Biotech has retained its rights to research, develop, manufacture, and commercialize certain licensed and option ADCs.

Similarly, in April 2023, BioNTech SE and Duality Biologics (Suzhou) Co. Ltd signed a strategic partnership agreement to develop next-generation ADCs to treat cancer and autoimmune diseases. Under the partnership agreement, BioNTech SE will have access to DualityBio's lead candidate, DB-1303. DB-1303 is a topoisomerase-1 inhibitor-based ADC directed against Human Epidermal Growth Factor Receptor 2 (HER2). HER2 is an overexpressed common target in most cancer types and contributes to cancer cells' aggressive growth and spread. Secondly, BioNTech SE will have access to another topoisomerase-1 inhibitor-based ADC candidate, DB-1311. Companies have aimed to transform and commercialize innovative therapies worldwide.

Antibody Drug Conjugates Market: Segmental Overview

The antibody drug conjugates market is segmented on the basis of technology, application, distribution channel, and geography. Based on technology, the antibody drug conjugates market is bifurcated into cleavable linkers and non-cleavable linkers. In 2022, the cleavable linkers segment held a larger market share, and the non-cleavable linkers segment is estimated to register a faster CAGR during 2022-2030. Cleavable linkers use a chemical trigger or inherent properties of their structure to release the cytotoxic payload in the tumor cells. This technology uses pH sensitivity, glutathione sensitivity, and protease sensitivity mechanisms as chemical triggers. The cleavable linker technology is widely used in developing antibody-drug conjugates (ADCs). According to the article "Antibody-drug conjugates: Recent advances in linker chemistry," published in March 2021, over 80% of the approved ADCs are made using cleavable linker technology. Besponsa (inotuzumab ozogamicin) and Adcetris (brentuximab vedotin) are two notable examples of ADCs synthesized using this technology. These ADCs remain comparatively stable for a long time in blood circulation after releasing hydrophilicity traceless payload. Moreover, cleavable linkers can release the payload intracellularly.

Based on application, the antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. In 2022, the breast cancer segment held the largest market share, and is estimated to register the fastest CAGR of 18.6% during 2022-2030. The use of ADCs has significantly transformed how breast cancer treatment is planned. The development of ADCs is expected to improve the potency, precision, and safety of breast cancer therapeutics. At present, Kadcyla/T-DM1 (ado-trastuzumab emtansine), Enhertu/T-DXd (trastuzumab deruxtecan), and Trodelvy/SG (sacituzumab govetican) are the commercialized products available in the market to treat triple-negative breast cancer (TNBC) and metastatic breast cancer cases. According to the Breast Cancer Research Foundation data, published in January 2023, 17 ADCs are in clinical trials. 9 out of these are HER2-directed ADCs, which are being studied in different combinations of payloads. The remaining 8 ADCs are being studied in combination with novel antibody targets.

Antibody Drug Conjugates Market: Geographical Overview

North America holds the largest share of the antibody drug conjugates market. The antibody drug conjugates market in this region is split into the US, Canada, and Mexico. The market growth in the region is attributed to increasing research and development for ADCs, rising product approvals, growing awareness about ADCs, and rising number of mergers, collaborations, and partnerships among the operating players. In addition, significantly growing incidences of cancer are among the other leading factors escalating the demand for ADCs.

The US is the largest contributor to the antibody drug conjugates market in North America and the world. The highest numbers of ADCs are approved in the US. By January 2021, the US Food and Drug Administration (FDA) had approved Mylotarg, Lumoxiti, Adcetris, Kadcyla, Enhertu, Trodelvy, Besponsa, Polivy, Padcev, and Blenrep for several cancer indications. In addition, several ADCs are in the pipeline in the US. ADCs have been developed with strategies such as advanced conjugate technologies, more potent payloads, targeting novel antigens, and novel linkers. According to the FDA's data published in May 2021, 113 clinical trials were in studies for 77 novel ADCs that targeted over 40 different targets. The growing list of ADCs in the pipeline is estimated to enhance the antibody drug conjugate market size in the country in the coming future.

In addition, growing partnerships among antibody drug conjugate market leader will expand their technologies in different regions enable market growth. In August 2023, ImmunoGen, Inc. and Takeda Pharmaceutical Company Limited collaborated to develop and commercialize ELAHERE, Immunogen's ADC therapy, in Japan. Under the collaboration agreement, ImmunoGen, Inc. receives upfront and additional payments upon conversion of FDA accelerated approval of ELAHERE to treat platinum-resistant ovarian cancer. If Takeda achieves certain regulatory and commercial milestones and double-digit royalties through the net sales of ELAHERE in Japan, it will pay an additional payment to ImmunoGen, Inc. Nevertheless, Immunogen has retained its exclusive production rights and will supply the product for development and commercialization in Japan. In return, Takeda will be responsible for all regulatory filing and have an exclusive license to develop and commercialize ELAHERE in Japan.

A few of the major primary and secondary sources referred to while preparing the ADC market report on the US Food and Drug Administration (FDA), Cancer.Net, EMA (European Medicines Agency), and Centers for Disease Control and Prevention (CDC).

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the antibody-drug conjugates.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global antibody-drug conjugates, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global antibody-drug conjugates trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Antibody Drug Conjugates Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 Global PEST Analysis
  • 4.3 List of Vendors
    • 4.3.1 List of Vendors in the Value Chain

5. Antibody Drug Conjugates Market - Key Industry Dynamics

  • 5.1 Key Market Drivers:
    • 5.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates
    • 5.1.2 Rising Incidences of Cancer Cases
    • 5.1.3 Increasing FDA Approvals for ADCs
  • 5.2 Market Restraints
    • 5.2.1 High Cost of ADCs Development and Commercialization
  • 5.3 Market Opportunities
    • 5.3.1 Increasing Investments to Develop ADCs
  • 5.4 Market Trends
    • 5.4.1 Escalating Pipeline of ADCs
  • 5.5 Impact Analysis:

6. Antibody Drug Conjugates Market - Global Market Analysis

  • 6.1 Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030

7. Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Technology

  • 7.1 Overview
  • 7.2 Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
  • 7.3 Cleavable Linker
    • 7.3.1 Overview
    • 7.3.2 Cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Non-cleavable Linker
    • 7.4.1 Overview
    • 7.4.2 Non-cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

8. Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Application

  • 8.1 Overview
  • 8.2 Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
  • 8.3 Blood Cancer
    • 8.3.1 Overview
    • 8.3.2 Blood Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Breast Cancer
    • 8.4.1 Overview
    • 8.4.2 Breast Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Ovarian Cancer
    • 8.5.1 Overview
    • 8.5.2 Ovarian Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.6 Urothelial Cancer
    • 8.6.1 Overview
    • 8.6.2 Urothelial Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.7 Others
    • 8.7.1 Overview
    • 8.7.2 Others: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

9. Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Distribution Channel

  • 9.1 Overview
  • 9.2 Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
  • 9.3 Hospital Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Hospital Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Retail Pharmacies
    • 9.4.1 Overview
    • 9.4.2 Retail Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Online Pharmacies
    • 9.5.1 Overview
    • 9.5.2 Online Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

10. Antibody Drug Conjugates Market - Regional Analysis

  • 10.1 North America Antibody Drug Conjugates Market, Revenue and Forecast To 2030
    • 10.1.1 Overview
    • 10.1.2 Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.1.3 North America: Antibody Drug Conjugates Market, by Technology
    • 10.1.4 North America: Antibody Drug Conjugates Market, by Application
    • 10.1.5 North America: Antibody Drug Conjugates Market, by Distribution Channel
    • 10.1.6 North America: Antibody Drug Conjugates Market, by Country
      • 10.1.6.1 US
        • 10.1.6.1.1 Overview
        • 10.1.6.1.2 US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.6.1.3 US: Antibody Drug Conjugates Market, by Technology
        • 10.1.6.1.4 US: Antibody Drug Conjugates Market, by Application
        • 10.1.6.1.5 US: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.1.6.2 Canada
        • 10.1.6.2.1 Overview
        • 10.1.6.2.2 Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.6.2.3 Canada: Antibody Drug Conjugates Market, by Technology
        • 10.1.6.2.4 Canada: Antibody Drug Conjugates Market, by Application
        • 10.1.6.2.5 Canada: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.1.6.3 Mexico
        • 10.1.6.3.1 Overview
        • 10.1.6.3.2 Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.6.3.3 Mexico: Antibody Drug Conjugates Market, by Technology
        • 10.1.6.3.4 Mexico: Antibody Drug Conjugates Market, by Application
        • 10.1.6.3.5 Mexico: Antibody Drug Conjugates Market, by Distribution Channel
  • 10.2 Europe Antibody Drug Conjugates Market, Revenue and Forecast To 2030
    • 10.2.1 Overview
    • 10.2.2 Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.2.3 Europe: Antibody Drug Conjugates Market, by Technology
    • 10.2.4 Europe: Antibody Drug Conjugates Market, by Application
    • 10.2.5 Europe: Antibody Drug Conjugates Market, by Distribution Channel
    • 10.2.6 Europe: Antibody Drug Conjugates Market, by Country
      • 10.2.6.1 UK
        • 10.2.6.1.1 Overview
        • 10.2.6.1.2 UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.1.3 UK: Antibody Drug Conjugates Market, by Technology
        • 10.2.6.1.4 UK: Antibody Drug Conjugates Market, by Application
        • 10.2.6.1.5 UK: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.2.6.2 Germany
        • 10.2.6.2.1 Overview
        • 10.2.6.2.2 Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.2.3 Germany: Antibody Drug Conjugates Market, by Technology
        • 10.2.6.2.4 Germany: Antibody Drug Conjugates Market, by Application
        • 10.2.6.2.5 Germany: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.2.6.3 France
        • 10.2.6.3.1 Overview
        • 10.2.6.3.2 France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.3.3 France: Antibody Drug Conjugates Market, by Technology
        • 10.2.6.3.4 France: Antibody Drug Conjugates Market, by Application
        • 10.2.6.3.5 France: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.2.6.4 Italy
        • 10.2.6.4.1 Overview
        • 10.2.6.4.2 Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.4.3 Italy: Antibody Drug Conjugates Market, by Technology
        • 10.2.6.4.4 Italy: Antibody Drug Conjugates Market, by Application
        • 10.2.6.4.5 Italy: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.2.6.5 Spain
        • 10.2.6.5.1 Overview
        • 10.2.6.5.2 Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.5.3 Spain: Antibody Drug Conjugates Market, by Technology
        • 10.2.6.5.4 Spain: Antibody Drug Conjugates Market, by Application
        • 10.2.6.5.5 Spain: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.2.6.6 Rest of Europe
        • 10.2.6.6.1 Overview
        • 10.2.6.6.2 Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.6.3 Rest of Europe: Antibody Drug Conjugates Market, by Technology
        • 10.2.6.6.4 Rest of Europe: Antibody Drug Conjugates Market, by Application
        • 10.2.6.6.5 Rest of Europe: Antibody Drug Conjugates Market, by Distribution Channel
  • 10.3 Asia Pacific Antibody Drug Conjugates Market, Revenue and Forecast To 2030
    • 10.3.1 Overview
    • 10.3.2 Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.3.3 Asia Pacific: Antibody Drug Conjugates Market, by Technology
    • 10.3.4 Asia Pacific: Antibody Drug Conjugates Market, by Application
    • 10.3.5 Asia Pacific: Antibody Drug Conjugates Market, by Distribution Channel
    • 10.3.6 Asia Pacific: Antibody Drug Conjugates Market, by Country
      • 10.3.6.1 China
        • 10.3.6.1.1 Overview
        • 10.3.6.1.2 China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.1.3 China: Antibody Drug Conjugates Market, by Technology
        • 10.3.6.1.4 China: Antibody Drug Conjugates Market, by Application
        • 10.3.6.1.5 China: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.3.6.2 Japan
        • 10.3.6.2.1 Overview
        • 10.3.6.2.2 Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.2.3 Japan: Antibody Drug Conjugates Market, by Technology
        • 10.3.6.2.4 Japan: Antibody Drug Conjugates Market, by Application
        • 10.3.6.2.5 Japan: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.3.6.3 India
        • 10.3.6.3.1 Overview
        • 10.3.6.3.2 India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.3.3 India: Antibody Drug Conjugates Market, by Technology
        • 10.3.6.3.4 India: Antibody Drug Conjugates Market, by Application
        • 10.3.6.3.5 India: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.3.6.4 South Korea
        • 10.3.6.4.1 Overview
        • 10.3.6.4.2 South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.4.3 South Korea: Antibody Drug Conjugates Market, by Technology
        • 10.3.6.4.4 South Korea: Antibody Drug Conjugates Market, by Application
        • 10.3.6.4.5 South Korea: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.3.6.5 Australia
        • 10.3.6.5.1 Overview
        • 10.3.6.5.2 Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.5.3 Australia: Antibody Drug Conjugates Market, by Technology
        • 10.3.6.5.4 Australia: Antibody Drug Conjugates Market, by Application
        • 10.3.6.5.5 Australia: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.3.6.6 Rest of Asia Pacific
        • 10.3.6.6.1 Overview
        • 10.3.6.6.2 Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.6.3 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Technology
        • 10.3.6.6.4 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Application
        • 10.3.6.6.5 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Distribution Channel
  • 10.4 Middle East & Africa Antibody Drug Conjugates Market, Revenue and Forecast To 2030
    • 10.4.1 Overview
    • 10.4.2 Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.4.3 Middle East & Africa: Antibody Drug Conjugates Market, by Technology
    • 10.4.4 Middle East & Africa: Antibody Drug Conjugates Market, by Application
    • 10.4.5 Middle East & Africa: Antibody Drug Conjugates Market, by Distribution Channel
    • 10.4.6 Middle East & Africa: Antibody Drug Conjugates Market, by Country
      • 10.4.6.1 Saudi Arabia
        • 10.4.6.1.1 Overview
        • 10.4.6.1.2 Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.6.1.3 Saudi Arabia: Antibody Drug Conjugates Market, by Technology
        • 10.4.6.1.4 Saudi Arabia: Antibody Drug Conjugates Market, by Application
        • 10.4.6.1.5 Saudi Arabia: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.4.6.2 UAE
        • 10.4.6.2.1 Overview
        • 10.4.6.2.2 UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.6.2.3 UAE: Antibody Drug Conjugates Market, by Technology
        • 10.4.6.2.4 UAE: Antibody Drug Conjugates Market, by Application
        • 10.4.6.2.5 UAE: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.4.6.3 South Africa
        • 10.4.6.3.1 Overview
        • 10.4.6.3.2 South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.6.3.3 South Africa: Antibody Drug Conjugates Market, by Technology
        • 10.4.6.3.4 South Africa: Antibody Drug Conjugates Market, by Application
        • 10.4.6.3.5 South Africa: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.4.6.4 Rest of Middle East & Africa
        • 10.4.6.4.1 Overview
        • 10.4.6.4.2 Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.6.4.3 Rest of Middle East & Africa: Antibody Drug Conjugates Market, by Technology
        • 10.4.6.4.4 Rest of Middle East & Africa: Antibody Drug Conjugates Market, by Application
        • 10.4.6.4.5 Rest of Middle East & Africa: Antibody Drug Conjugates Market, by Distribution Channel
  • 10.5 South & Central America Antibody Drug Conjugates Market, Revenue and Forecast To 2030
    • 10.5.1 Overview
    • 10.5.2 Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.5.3 South & Central America: Antibody Drug Conjugates Market, by Technology
    • 10.5.4 South & Central America: Antibody Drug Conjugates Market, by Application
    • 10.5.5 South & Central America: Antibody Drug Conjugates Market, by Distribution Channel
    • 10.5.6 South & Central America: Antibody Drug Conjugates Market, by Country
      • 10.5.6.1 Brazil
        • 10.5.6.1.1 Overview
        • 10.5.6.1.2 Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.5.6.1.3 Brazil: Antibody Drug Conjugates Market, by Technology
        • 10.5.6.1.4 Brazil: Antibody Drug Conjugates Market, by Application
        • 10.5.6.1.5 Brazil: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.5.6.2 Argentina
        • 10.5.6.2.1 Overview
        • 10.5.6.2.2 Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.5.6.2.3 Argentina: Antibody Drug Conjugates Market, by Technology
        • 10.5.6.2.4 Argentina: Antibody Drug Conjugates Market, by Application
        • 10.5.6.2.5 Argentina: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.5.6.3 Rest of South & Central America
        • 10.5.6.3.1 Overview
        • 10.5.6.3.2 Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.5.6.3.3 Rest of South & Central America: Antibody Drug Conjugates Market, by Technology
        • 10.5.6.3.4 Rest of South & Central America: Antibody Drug Conjugates Market, by Application
        • 10.5.6.3.5 Rest of South & Central America: Antibody Drug Conjugates Market, by Distribution Channel

11. Antibody Drug Conjugates Market-Industry Landscape

  • 11.1 Overview
  • 11.2 Organic Growth Strategies
    • 11.2.1 Overview
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Companies' Manufacturing Capacities and Capabilities

12. Company Profiles

  • 12.1 ADC Therapeutics SA
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Pfizer Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Hoffmann-La Roche Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 ImmunoGen, Inc.
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 GSK Plc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Gilead Sciences Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 AstraZeneca Plc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Astellas Pharma Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 RemeGen Co Ltd
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Takeda Pharmaceutical Co Ltd
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Antibody Drug Conjugates Market Segmentation
  • Table 2. List of Vendors
  • Table 3. New Cancer Cases Worldwide, in 2020
  • Table 4. List of FDA-Approved ADCs
  • Table 5. North America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 6. North America: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) - Application
  • Table 7. North America: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) - Distribution Channel
  • Table 8. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 9. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 10. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 11. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 12. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 13. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 14. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 15. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 16. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 17. Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 18. Europe: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) - Application
  • Table 19. Europe: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) - Distribution Channel
  • Table 20. UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 21. UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 22. UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 23. Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 24. Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 25. Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 26. France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 27. France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 28. France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 29. Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 30. Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 31. Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 32. Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 33. Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 34. Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 35. Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 36. Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 37. Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 38. Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 39. Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) - Application
  • Table 40. Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) - Distribution Channel
  • Table 41. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 42. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 43. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 44. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 45. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 46. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 47. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 48. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 49. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 50. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 51. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 52. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 53. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 54. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 55. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 56. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 57. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 58. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 59. Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 60. Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) - Application
  • Table 61. Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) - Distribution Channel
  • Table 62. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 63. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 64. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 65. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 66. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 67. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 68. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 69. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 70. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 71. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 72. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 73. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 74. South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 75. South & Central America: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) - Application
  • Table 76. South & Central America: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) - Distribution Channel
  • Table 77. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 78. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 79. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 80. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 81. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 82. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 83. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 84. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 85. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 86. Recent Organic Growth Strategies in Antibody Drug Conjugates Market
  • Table 87. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market
  • Table 88. Glossary of Terms, Antibody Drug Conjugates Market

List Of Figures

  • Figure 1. Antibody Drug Conjugates Market Segmentation, By Region
  • Figure 2. Key Insights
  • Figure 3. Global - PEST Analysis
  • Figure 4. Antibody Drug Conjugates Market - Key Industry Dynamics
  • Figure 5. Impact Analysis of Drivers and Restraints
  • Figure 6. Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030
  • Figure 7. Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
  • Figure 8. Cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Non-Cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
  • Figure 11. Blood Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Breast Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Ovarian Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Urothelial Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Others: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
  • Figure 17. Hospital Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Retail Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Online Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Antibody Drug Conjugates Market, 2022 ($Mn)
  • Figure 21. Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 22. North America: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
  • Figure 23. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 24. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 25. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 26. Antibody Drug Conjugates Market, 2022 ($Mn)
  • Figure 27. Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 28. Europe: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
  • Figure 29. UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 30. Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 31. France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 32. Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 33. Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 34. Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 35. Antibody Drug Conjugates Market, 2022 ($Mn)
  • Figure 36. Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 37. Asia Pacific: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
  • Figure 38. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 39. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 40. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 41. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 42. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 43. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 44. Antibody Drug Conjugates Market, 2022 ($Mn)
  • Figure 45. Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 46. Middle East & Africa: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
  • Figure 47. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 48. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 49. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 50. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 51. Antibody Drug Conjugates Market, 2022 ($Mn)
  • Figure 52. Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 53. South & Central America: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
  • Figure 54. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 55. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 56. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)